Download PDF
TumorDiagnostik & Therapie 2002; 23(2): 57-61
DOI: 10.1055/s-2002-26771
Originalarbeit/Original Article
© Georg Thieme Verlag Stuttgart · New York

Combination of mitoxantrone and etoposide in the Treatment of Advanced Myelodysplastic
Syndrome/Secondary Acute Myeloid Leukemia - a Multicenter Phase II Study

Kombinationschemotherapie mit Mitoxantron und Etoposid bei der Behandlung des fortgeschrittenen myelodysplastischen Syndroms/sekundärer akuter myeloischer Leukämie - eine multizentrische Phase II-StudieC.  Baldus1 , L.  Balleisen2 , W.  Hirschmann3 , C.  Rudolph4 , H.  Bartels5 , N.  Grobe6 , T.  Zwingers7 , E.  Thiel1 , W.  U.  Knauf1
  • 1Medizinische Klinik III, Universitätsklinikum Benjamin Franklin der Freien Universität Berlin
  • 2Abt. Hämatologie und Onkologie, Evangelisches Krankenhaus, Hamm
  • 3Abt. Hämatologie und Onkologie, Städtische Kliniken, Kassel
  • 4Medizinische Klinik II, Karl-Thiem-Klinikum, Cottbus
  • 5Abt. Hämatologie und Onkologie, Städtisches Krankenhaus Süd, Lübeck
  • 6Medizinische Klinik I, Neubrandenburg
  • 7estimate GmbH, Augsburg
Further Information

Publication History

Publication Date:
02 May 2002 (online)

Also available at
    Permissions and Reprints

Abstract

Background: The combination of mitoxantrone plus etoposide (NOVE) has been shown to be effective in the treatment of relapsed AML and AML in elderly patients. In order to further evaluate this regimen, we conducted a phase II study on NOVE in previously untreated patients diagnosed with sAML/advanced MDS (RAEBt). Patients: A total of 42 evaluable patients with a median age of 61 years (range 37 - 73) were analyzed. Median LDH was 315 U/l (range 67 - 1480) at time of diagnosis. Treatment was initiated within one month from diagnosis in 57 % of patients. NOVE consisted of mitoxantrone 10 mg/sqm d1 - 5 plus etoposide 100 mg/sqm d1 - 5. 15 patients received a second cycle NOVE. Results: Best response was CR in 15 patients (35 %), PR (eg. remaining features of MDS with blast cell count < 10 % in the bone marrow) in 6 patients (15 %), whereas 21 (50 %) patients were non-responders. Correlation with response was observed neither for FAB subtype nor for level of initial LDH. Overall, NOVE was well tolerated. However, three early deaths were reported. The median survival for all 42 patients was 175 days with an estimated overall survival of 20 % at 283 days. Conclusion: In summary, NOVE was demonstrated to be a palliative treatment option for patients with sAML/RAEBt showing a low toxicity profile and leading to an overall response rate of 50 %. Thus, it should be taken into consideration for treatment of this poor prognosis subtype of acute leukemia whenever allogeneic stem cell transplantation cannot be performed.

Key words

Secondary acute myeloid leukemia - Myelodysplastic syndrome - Mitoxantrone - Etoposide

References

  • 1 Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennet J. International scoring system for evaluating prognosis in myelodysplastic syndromes.  Blood. 1997;  89 2079-2088
    PubMedGoogle Scholar
  • 2 Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes.  Br J Haematol. 1992;  82 358-367
    PubMedGoogle Scholar
  • 3 Leone G, Mele L, Pusoni A, Equitani F, Pagano L. The incidence of secondary leukemias.  Haematologica. 1999;  84 97-945
    PubMedGoogle Scholar
  • 4 Johnson P RE, Liu Yin J A. Acute myeloid leukemia in the elderly: biology and treatment.  Br J Haematol. 1993;  83 1-6
    PubMedGoogle Scholar
  • 5 Leith C P, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I M, Head D R, Appelbaum F R, Willman C L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group Study.  Blood. 1997;  89 3323-3329
    PubMedGoogle Scholar
  • 6 Willman C L. Molecular genetic features of myelodysplastic syndromes.  Leukemia. 1998;  12 (1) S2-6
    PubMedGoogle Scholar
  • 7 Foucar K, Langdon R M, Aritage J O, Olson D, Carol T J. Myelodysplastic syndromes: a clinical and pathological analysis of 109 cases.  Cancer. 1985;  56 553-561
    PubMedGoogle Scholar
  • 8 Economopoulos T, Stathakis N, Foudoulakis A, Papadoulis N, Dervenoulas J, Papageorgio E, Anastassiou C, Hadjioannou J, Raptis S. Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification.  Eur J Haematol. 1987;  38 338-344
    PubMedGoogle Scholar
  • 9 Arlin Z, Case D C, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K. Randomized multicenter trial of cytarabine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia.  Leukemia. 1990;  4 177-183
    PubMedGoogle Scholar
  • 10 Loewenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker A W, Berneman Z N, Thyss A, van de Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.  J Clin Oncol. 1998;  16 872-881
    PubMedGoogle Scholar
  • 11 Ho A D, Lipp T, Ehninger G, Illiger H J, Meyer P, Freund M, Hunstein W. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia - an active and well tolerated regime.  J Clin Oncol. 1988;  6 213-217
    PubMedGoogle Scholar
  • 12 Knauf W U, Ho A D, Koerbling M, Hunstein W. Combination therapy with mitoxantrone and etoposide in acute myelogenous leukemia of adults. In: Büchner T (eds), Schellong G, Hiddemann W, Ritter J Haematology and Blood Transfusion. Acute Leukaemias. Berlin, Heidelberg; Springer 1990 33: 314-315
    Google Scholar
  • 13 Ehninger G, Fackler-Schwalbe E, Freund M, Heil G, Henke M, Hoelzer D. Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. In: Büchner T (eds), Schellong G, Hiddemann W, Ritter J Haematology and Blood Transfusion. Acute Leukaemias. Berlin, Heidelberg; Springer 1990 33: 316-317
    Google Scholar
  • 14 Visani G, Pagano L, Pulsoni A, Tosi P, Piccaluga P P, Pastano R, Grafone T, Malagola M, Isidori A, Tura S. Chemotherapy of secondary leukemias.  Leukemia and Lymphoma. 2000;  37 543-549
    PubMedGoogle Scholar
  • 15 Knauf W U, Berdel W E, Ho A D, Kreuser E D, Thiel E. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia.  Leukemia and Lymphoma. 1994;  12 421-425
    PubMedGoogle Scholar
  • 16 Bennett J M, Catovski D, Daniel M, Flandrin M, Galton D AG, Gralnick H R. French-American-British (FAB) Cooperative Group . Proposals for the classification of the myelodysplastic syndromes.  Br J Haematol. 1982;  51 189-199
    PubMedGoogle Scholar
  • 17 Bennett J M, Catovski D, Daniel M, Flandrin M, Galton D AG, Gralnick H R. French-American-British (FAB) Cooperative Group . Proposals for the classification of the acute leukemias.  Br J Haematol. 1976;  33 451-458
    CrossrefPubMedGoogle Scholar
  • 18 Kaplan E, Meier P. Nonparametric estimation from incomplete observation.  J Am Stat Assoc. 1958;  53 457
    CrossrefPubMedGoogle Scholar
  • 19 Steinmetz H AT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, Franklin J, Tesch H, Diehl V, Wickramanayake P D. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.  Ann Hematol. 1999;  78 418-425
    CrossrefPubMedGoogle Scholar
  • 20 Chauncey T R, Rankin C, Anderson J E, Chen I M, Kopecky K J, Godwin J E, Kalaycio M E, Moore D F, Shurafa M S, Petersdorf S H, Kraut E H, Leith C P, Head D R, Luthardt W, Willmann C L, Appelbaum A. Phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A Southwest Oncology Group Study 9617.  Leukemia Res. 2000;  24 567-574
    CrossrefPubMedGoogle Scholar
  • 21 Ganser A, Hei G, Seipelt G, Hofmann W, Fischer J T, Langer W, Brockhaus W, Kolbe K, Ittel H, Brack N, Fuhr H G, Knuth P, Höffken K, Bergmann L, Hoelzer D. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute myeloid leukemia (AML).  Ann Hematol. 2000;  79 30-35
    CrossrefPubMedGoogle Scholar
  • 22 Kantarjian H M, Keating M J, Walters R S, Smith T L, Cork A, McCredie K B, Freireich E J. Therapy-related leukemia and myelodysplastic syndrome. Clinical, cytogenetic, and prognostic features.  J Clin Oncol. 1986;  12 1748-1757
    PubMedGoogle Scholar
  • 23 Campos L, Guyotat D, Archimbaud E, Calmard O P, Tsuruo T, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.  Blood. 1992;  79 473-476
    PubMedGoogle Scholar
  • 24 Leith C P, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I M, Head D R, Appelbaum F R, Willman C L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study.  Blood. 1997;  89 3323-3329
    PubMedGoogle Scholar
  • 25 Poulain S, Lepelley P, Preudhomme C, Cambier N, Cornillon J, Wattel E, Cosson A, Fenaux P. Expression of the multidrug resistance-associated protein in myelodysplastic syndromes.  Br J Haematol. 2000;  111 591-598
    PubMedGoogle Scholar
  • 26 Wattel E, Solary E, Hequet B, Caillot D, Ifrah N, Brion A, Mahe B, Milpied N, Janvier M, Guerci A, Roachant H, Cordonnier C, Dreyfus F, Buzyn A, Hoang-Ngoc L, Stoppa A M, Gratecos N, Sadoun A, Stamatoulas A, Tilly H, Brice P, Maloisel F, Lioure B, Desablens B, Pignon B, Abgrall J P, Leporrier M, Dupriez B, Guyotat D, Lepelley P, Fenaux P. Quinine improves the result of intensive chemotherapy in myelodysplastic syndromes expressing P-glycoprotein: results of a randomized study.  Br J Haematol. 1998;  102 1015-1024
    CrossrefPubMedGoogle Scholar
  • 27 Cazzola M, Anderson J E, Ganser A, Hellström-Lindberg A. A patient oriented approach to treatment of myelodysplastic syndromes.  Haematologica. 1998;  83 920-935
    PubMedGoogle Scholar
  • 28 Ohno R, Tomonaga M, Kobayashi T, Kanamuru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yokomaku S, Nakayama S, Yoshida Y, Miura A B, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia.  N Engl J Med. 1990;  323 871-877
    PubMedGoogle Scholar
  • 29 Dombret H, Chastang C, Fenaux P, Reiffers J, Bordesoulle D, Bouadballah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia.  N Engl J Med. 1995;  332 1678-1683
    CrossrefPubMedGoogle Scholar
  • 30 Ganser A. Aggressive chemotherapy with G-CSF priming is effective for advanced myelodysplastic syndromes and high risk acute myeloid leukemia.  Trends Onco-Hematol. 1997;  5 3-4
    PubMedGoogle Scholar
  • 31 De Witte T. Stem cell transplantation for patients with myelodysplastic syndrome and secondary leukemias.  Int J Hematol. 2000;  72 151-156
    PubMedGoogle Scholar
  • 32 Feldmann E, Kalaycio M, Schulman P, Frankel S, Weiner G, Scharzberg L, Velez-Garcia E, Jurcic J, Scheinberg D, Wedel N. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): preliminary report of a phase II study.  Proc Am Soc Clin Oncol (abstract). 1999;  18 12
    PubMedGoogle Scholar
  • 33 Jurcic J G, DeBlasio A, Dumont L, Yao T J, Scheinberg D A. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute premyelocytic leukemia (APL).  Clin Cancer Res. 2000;  6 372-380
    PubMedGoogle Scholar
  • 34 Sievers E L, Appelbaum R A, Spielberger R T, Forman S J, Flowers D, Smith F O, Shannon-Dorcy K, Berger M S, Bernstein I D. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamycin immunoconjugate.  Blood. 1999;  93 3678-3684
    PubMedGoogle Scholar

Prof. Dr. W. Knauf

Medizinische Klinik III, Universitätsklinikum Benjamin Franklin der
Freien Universität Berlin

Hindenburgdamm 30

11220 Berlin

Germany

Phone: + 49-30-8445-4550

Fax: + 49-30-8445-4021

Email: knauf@ukbf.fu-berlin.de

      >